TY - JOUR
T1 - Guidelines for mitochondrial RNA analysis
AU - Jusic, Amela
AU - Erpapazoglou, Zoi
AU - Dalgaard, Louise Torp
AU - Lakkisto, Päivi
AU - de Gonzalo-Calvo, David
AU - Benczik, Bettina
AU - Ágg, Bence
AU - Ferdinandy, Péter
AU - Fiedorowicz, Katarzyna
AU - Schroen, Blanche
AU - Lazou, Antigone
AU - Devaux, Yvan
AU - AtheroNET COST Action CA21153
N1 - Acknowledgments
This article is based upon work from COST Action EU-CardioRNA, CA17129, and COST Action AtheroNET, CA21153, supported by COST (European Cooperation in Science and Technology). A.J. is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions individual fellowship (grant agreement 893435). L.T.D. is funded by the Innovation Fund Denmark (1044-00139B) and the Novo Nordisk Foundation (NNF22OC0078203). Y.D. is funded by the EU Horizon 2020 project COVIRNA (grant agreement 101016072), the National Research Fund (grant nos. C14/BM/8225223, C17/BM/11613033, and COVID-19/2020-1/14719577/miRCOVID), the Ministry of Higher Education and Research of Luxembourg, and the Heart Foundation-Daniel Wagner of Luxembourg. DdG-C has received financial support from the Instituto de Salud Carlos III (Miguel Servet 2020: CP20/00041), co-funded by the European Union. CIBERES (CB07/06/2008) is an initiative of the Instituto de Salud Carlos III. P.L. is funded by the Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, The Finnish Society of Clinical Chemistry, and the Finnish Foundation for Laboratory Medicine. K.F. is funded by the National Centre for Research and Development, Poland, grant no. DWM/WPC2/285/2020 and NCN Miniatura 5 2021/05/X/NZ3/01013. P.F. and B.Á. were funded by project no. RRF-2.3.1-21-2022-00003 that has been implemented with the support provided by the European Union. The 2020-1.1.5-GYORSÍTÓSÁV-2021-00011 project was funded by the Ministry for Innovation and Technology with support from the National Research Development and Innovation Fund under the 2020-1.1.5-GYORSÍTÓSÁV call programme. This study was funded by the by grant 2020-1.1.6-JÖVŐ-2021-00013 (“Befektetés a jövőbe” NKFIH). This project has received funding from the HUN-REN Hungarian Research Network.
Publisher Copyright:
© 2024 The Author(s)
PY - 2024/9/10
Y1 - 2024/9/10
N2 - Mitochondria are the energy-producing organelles of mammalian cells with critical involvement in metabolism and signaling. Studying their regulation in pathological conditions may lead to the discovery of novel drugs to treat, for instance, cardiovascular or neurological diseases, which affect high-energy-consuming cells such as cardiomyocytes, hepatocytes, or neurons. Mitochondria possess both protein-coding and noncoding RNAs, such as microRNAs, long noncoding RNAs, circular RNAs, and piwi-interacting RNAs, encoded by the mitochondria or the nuclear genome. Mitochondrial RNAs are involved in anterograde-retrograde communication between the nucleus and mitochondria and play an important role in physiological and pathological conditions. Despite accumulating evidence on the presence and biogenesis of mitochondrial RNAs, their study continues to pose significant challenges. Currently, there are no standardized protocols and guidelines to conduct deep functional characterization and expression profiling of mitochondrial RNAs. To overcome major obstacles in this emerging field, the EU-CardioRNA and AtheroNET COST Action networks summarize currently available techniques and emphasize critical points that may constitute sources of variability and explain discrepancies between published results. Standardized methods and adherence to guidelines to quantify and study mitochondrial RNAs in normal and disease states will improve research outputs, their reproducibility, and translation potential to clinical application.
AB - Mitochondria are the energy-producing organelles of mammalian cells with critical involvement in metabolism and signaling. Studying their regulation in pathological conditions may lead to the discovery of novel drugs to treat, for instance, cardiovascular or neurological diseases, which affect high-energy-consuming cells such as cardiomyocytes, hepatocytes, or neurons. Mitochondria possess both protein-coding and noncoding RNAs, such as microRNAs, long noncoding RNAs, circular RNAs, and piwi-interacting RNAs, encoded by the mitochondria or the nuclear genome. Mitochondrial RNAs are involved in anterograde-retrograde communication between the nucleus and mitochondria and play an important role in physiological and pathological conditions. Despite accumulating evidence on the presence and biogenesis of mitochondrial RNAs, their study continues to pose significant challenges. Currently, there are no standardized protocols and guidelines to conduct deep functional characterization and expression profiling of mitochondrial RNAs. To overcome major obstacles in this emerging field, the EU-CardioRNA and AtheroNET COST Action networks summarize currently available techniques and emphasize critical points that may constitute sources of variability and explain discrepancies between published results. Standardized methods and adherence to guidelines to quantify and study mitochondrial RNAs in normal and disease states will improve research outputs, their reproducibility, and translation potential to clinical application.
KW - gene expression
KW - guidelines
KW - microRNAs
KW - mitochondria
KW - MT: Non-coding RNAs
KW - noncoding RNAs
UR - http://www.scopus.com/inward/record.url?scp=85198012146&partnerID=8YFLogxK
U2 - 10.1016/j.omtn.2024.102262
DO - 10.1016/j.omtn.2024.102262
M3 - Review article
AN - SCOPUS:85198012146
SN - 2162-2531
VL - 35
JO - Molecular Therapy - Nucleic Acids
JF - Molecular Therapy - Nucleic Acids
IS - 3
M1 - 102262
ER -